APA (7th ed.) Citation

Wenwang Lang, Qi Ai, Wenwen Zhang, Qinling Jiang, Yulong He, & Ming Ouyang. (2024). Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: Perspectives from the United States and China. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Wenwang Lang, Qi Ai, Wenwen Zhang, Qinling Jiang, Yulong He, and Ming Ouyang. Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Perspectives from the United States and China. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Wenwang Lang, et al. Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Perspectives from the United States and China. Frontiers Media S.A., 2024.